Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation

• Autorzy: Zimecki M , Weber-Dabrowska B. , Lusiak-Szelachowska M , Mulczyk M. , Boratynski J. , Pozniak G. , Syper D. , Gorski A.
• Języki publikacji: EN

Abstrakty

EN

The aim of this investigation was to reveal the regulatory properties of bacteriophage preparations in a model of mitogen-induced splenocyte proliferation in mice. We showed that sepharose 4B-purified preparations of the Staphylococcus aureus phage A20/R exhibited costimulatory activity in splenocyte proliferation induced by suboptimal (0.25 μg/ml) concentrations of ConA. On the other hand, the purified phage fraction was regulatory with regard to splenocyte proliferation induced by the optimal (2.5 μg/ml) ConA concentration. We also showed that the phage preparation can elicit IL-6 production in splenocyte cultures and enhance ConA-induced production of that cytokine. Furthermore, the phages preferentially induced IL-6 production in adherent splenocytes and increased levels of that cytokine in cultures of peritoneal cells from mice and rats. This phenomenon may explain the costimulatory activity of phages in the model described.

Słowa kluczowe

EN

bacteriophage; interleukin 6; regulation; regulatory signal; splenocyte proliferation; concanavalin A

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2003
• Tom: 08
• Numer: 3
• Opis fizyczny: p.699-711,fig.

Twórcy

autor

Zimecki M

• Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland

autor

Weber-Dabrowska B.

autor

Lusiak-Szelachowska M

autor

Mulczyk M.

autor

Boratynski J.

autor

Pozniak G.

autor

Syper D.

autor

Gorski A.

Bibliografia

• 1.Cohen, M.L. Epidemiology of drug-resistance: Implications for a post antimicrobial era. Science 257 (1992) 1050-1055.
• 2.Neu, H.C. The crisis in antibiotic resistance. Science 257 (1992) 1064-1071.
• 3.Lorch, A. Bacteriophages as an alternative to antibiotics. Biotech. Develop. Monitor 39 (1999) 14-17.
• 4.Barrow, P.A. and Soothill, J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5 (1997) 258-271.
• 5.Carlton, R.M. Phage therapy: past history and future prospect. Arch. Immunol. Ther. Exp. 47 (1999) 267-274.
• 6.Weber-Dąbrowska, B., Mulczyk, M. and Górski, A. Bacteriophage therapy of bacterial infections: an update of our Institute’s experience. Arch. Immunol. Ther. Exp. 48 (2000) 547-551.
• 7.Weber-Dąbrowska, B., Zimecki, M. and Mulczyk, M. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp. 48 (2000) 31-38.
• 8.Weber-Dąbrowska, B., Zimecki, M., Mulczyk, M. and Górski, A. Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol. Med. Microb. 34 (2002) 135-138.
• 9.Bloch, H. Experimental investigation of the relationship between bacteriophages and malignant tumors (in German). Arch. Ges. Virusforsch. 1 (1940) 481-492.
• 10.Kańtoch, M. and Mordarski, M. Binding of bacterial viruses by tumor cells in vitro, (in Polish), Post. Hig. Med. Dośw. 12 (1958) 191-192.
• 11.Wenger, S.L., Turner, J.H. and Petricciani, J.C. The cytogenetic, proliferative and viability effects of four bacteriophages on human lymphocytes. In Vitro 14 (1978) 543-549.
• 12.Snippe, H., de Reuver, M.J., Beider, M. and Willers, J.M. Bacteriophage MS-2 in the immune response. Int. Arch. Allergy. Appl. Immunol. 50 (1976) 111-122.
• 13.Fukumoto, T., Torigoe, N., Kawabata, S., Murakami, M., Uede, T., Nishi, T., Ito, Y. and Sugimura, K. Peptide mimics of the CTLA4-binding domain stimulate T cell. Nat. Biotechnol. 16 (1998) 237-238.
• 14.Holliger, P. and Riechmann, L. A conserved infection pathway for filamentous bacteriophages is suggested by the structure of the membrane penetration domain of the minor coat protein g3p from phage fd. Structure 5 (1997) 265-275.
• 15.Plunkett, G. 3rd, Rose, D.J., Durfee, T.J. and Blattner, F.R. Sequence of Shiga toxin 2 phage 933W from Escherichia coli 0157:H7:Shiga toxin as a late-gene product. J. Bacteriol. 181 (1999) 1767-1778.
• 16.Ślopek, S., Durlakowa, I., Weber-Dąbrowska, B., Kucharewicz-Krukowska, A., Dąbrowski M. and Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 31 (1983) 267-291.
• 17.Romanowska, E. Sepharose gel filtration method of purification of lipopolysaccharides. Anal. Biochem. 33 (1970) 383-389.
• 18.Bodzek, M. Physicochemical characterization of ultrafiltration membranes. Pol. J. Chem. 57 (1983) 919-930.
• 19.Hansen, M.B., Nielsen, S.E. and Berg, K. Re-examination and further development of a precise rapid dye method for measuring cell growth/cell kill. J. Immunol. Method. 119 (1989) 203-210.
• 20.Van Snick, J., Vink, A., Uyttenhove, C., Coulie, P.G., Rubira, M.R. and Simpson, R.J. Purification and NH2-terminal amino acid sequence of a T cell derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Nat. Acad. Sci. USA 83 (1986) 9679-9683.
• 21.Ceuppens, J.L., Baroja, M.L., Lovre, K., Van Damme, J. and Billau, A. Human T cell activation with phytohemaglutinnin. The function of IL-6 as an accessory signal. J. Immunol. 14 (1988) 3868-3874.
• 22.Kawakami, K., Kakimoto, K., Shinbori, T. and Onone, K. Signal by physical interaction and soluble factors accessory cells in the induction of receptor-mediated T-cell proliferation. Synergistic effect of BSF-2/IL-6 and IL-1. Immunology 67 (1989) 314-320.
• 23.Welborn, M.B. 3rd, Van Zee, K., Edwards, P.D., Pruitt, J.H., Kaibara, A., Vauthey, J.N., Rogy, M., Castelman, W.L., Lowry, S.F., Kenney, J.S., et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J. Exp. Med. 184 (1966) 165-171.
• 24.Wang, J.E., Jörnsen, P.F., Almlöf, M., Thiemermann, C., Foster S.J., Aasen, A.O. and Solberg, R. Peptidoglycan and lipoteichoic acid Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6) and IL-10 production in both T cells and monocytes in a human whole blood model. Inf. Immunity 68 (2000) 3965-70.